{"protocolSection": {"identificationModule": {"nctId": "NCT01841281", "orgStudyIdInfo": {"id": "271515"}, "secondaryIdInfos": [{"id": "R01HL105573", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01HL105573"}, {"id": "UCD105573", "type": "OTHER", "domain": "UC Davis"}], "organization": {"fullName": "University of California, Davis", "class": "OTHER"}, "briefTitle": "L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels", "officialTitle": "Phase II Study of L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Level"}, "statusModule": {"statusVerifiedDate": "2020-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-08"}, "primaryCompletionDateStruct": {"date": "2018-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-04-23", "studyFirstSubmitQcDate": "2013-04-25", "studyFirstPostDateStruct": {"date": "2013-04-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-11-04", "resultsFirstSubmitQcDate": "2020-04-20", "resultsFirstPostDateStruct": {"date": "2020-04-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-04-20", "lastUpdatePostDateStruct": {"date": "2020-04-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Nicholas Kenyon", "investigatorTitle": "Professor", "investigatorAffiliation": "University of California, Davis"}, "leadSponsor": {"name": "Nicholas Kenyon", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The major impact of this study will be to identify the adult severe asthma cohort that will benefit from supplemental L-arginine therapy. The investigators hypothesize that a subset of adult severe asthma patients will respond to supplemental L-arginine and derive clinical benefit from the addition of this therapy to standard-of-care asthma medications. The investigators hypothesize that the patients that benefit most will have low exhaled nitric oxide concentrations (\\< 20 ppb) at baseline.", "detailedDescription": "We hypothesize that a subset of adult severe asthma patients will respond to supplemental L-arginine and derive clinical benefit from the addition of this therapy to standard-of-care medications. We hypothesize that these patients will have lower exhaled NO concentrations (\\<20 ppb) and lower nitric oxide synthase 2 (NOS2)/ arginase I (Arg1) mRNA ratios in their airway epithelial cells than \"non-responders.\" The aim is to test the hypothesis that adult severe asthma subjects with exhaled breath NO concentrations \\< 20 ppb will have fewer American Thoracic Society (ATS)-defined asthma exacerbations over 3 months when treated with L-arginine compared to subjects with exhaled nitric oxide concentration (FeNO) \\> 25 ppb. The major impact of this study will be to identify the adult severe asthma cohort that will benefit from supplemental L-arginine therapy to define the underlying mechanisms of arginine benefit in asthma. This follows our initial 20 subject trial of L-arginine in asthma subjects (Kenyon et al., Pharmaceuticals 2011) that was designed to determine how L-arginine was metabolized (by testing serum markers) and whether certain participants had clinical benefit.\n\nTo do this, we will recruit a total of 50 ATS-defined severe asthmatic subjects with ongoing asthma exacerbations in past two months and enroll them in a randomized, blinded, placebo-controlled, cross-over designed trial of L-arginine and placebo. We will compare 25 subjects with \"low\" FeNO \\< 20 with 25 subjects that have \"high\" FeNO \\> 25 ppb."}, "conditionsModule": {"conditions": ["Asthma", "Inflammation"], "keywords": ["Asthma", "Severe Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 54, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Low Exhaled Nitric Oxide (NO)", "type": "ACTIVE_COMPARATOR", "description": "Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.\n\nAll subjects will receive L-arginine and placebo in this cross-over design study.", "interventionNames": ["Drug: L-Arginine", "Drug: Placebo"]}, {"label": "High Exhaled Nitric Oxide (NO)", "type": "ACTIVE_COMPARATOR", "description": "Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.\n\nAll subjects will receive L-arginine and placebo in this cross-over design study.", "interventionNames": ["Drug: L-Arginine", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "L-Arginine", "description": "L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.", "armGroupLabels": ["High Exhaled Nitric Oxide (NO)", "Low Exhaled Nitric Oxide (NO)"], "otherNames": ["Arginine 1000 (Jarrow Formulas, Los Angeles, CA)"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.", "armGroupLabels": ["High Exhaled Nitric Oxide (NO)", "Low Exhaled Nitric Oxide (NO)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Acute Exacerbation at 3 Months", "description": "The primary endpoint of the study is the number of acute moderate exacerbations at 3 months. A moderate asthma exacerbation is defined as any of the following: 1) A drop in morning peak flow rate (PEFR) \\>30% from baseline on 2 consecutive days (1 event), 2) Need for initiation of oral steroids or am increased dose of inhaled corticosteroids on any two consecutive days (1 event), 3) Doubling of short-acting \u03b2-agonist use (e.g. number of puffs of albuterol) per day for 2 consecutive days (1 event).", "timeFrame": "3 month"}], "secondaryOutcomes": [{"measure": "Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC)", "description": "The secondary endpoint is the change in FEV1/FVC ratio at 3 months. This calcuation is a ratio between the volume of breath exhaled in the first second divided by the total amount of breath exhaled in a vital capacity maneuver. A normal ratio is usually \\> 70%.", "timeFrame": "3 month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adults \\>18 yrs of age\n* Diagnosis of severe asthma based on American Thoracic Society Workshop definition (Am J Respir Crit Care Med 2000; 162:2341)\n* Active asthma medications of high dose inhaled corticosteroids plus long-acting beta agonist\n* History of recent asthma exacerbations or Asthma control test score \\< 20/25\n\nExclusion Criteria:\n\n* \\<19 yrs of age\n* Forced expiratory volume 1sec \\<30% predicted\n* Pregnant or nursing women\n* Current smokers or smoking history \\> 15 pack years\n* Actively taking or known intolerance to L-arginine", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "19 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Nicholas Kenyon, MD,MS", "affiliation": "Univ. of California, Davis", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "UC Davis CTSC Clinical Research Center", "city": "Sacramento", "state": "California", "zip": "95817", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}]}, "referencesModule": {"references": [{"pmid": "32497023", "type": "DERIVED", "citation": "Liao SY, Showalter MR, Linderholm AL, Franzi L, Kivler C, Li Y, Sa MR, Kons ZA, Fiehn O, Qi L, Zeki AA, Kenyon NJ. l-Arginine supplementation in severe asthma. JCI Insight. 2020 Jul 9;5(13):e137777. doi: 10.1172/jci.insight.137777."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants were assigned to low or high exhaled nitric oxide groups based on their levels at time of Visit 1.", "recruitmentDetails": "54 subjects consented and enrolled for the trial, but n=50 were randomized as n=4 participants declined to participate.", "groups": [{"id": "FG000", "title": "Low Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo", "description": "Subjects with a baseline exhaled NO level less than or equal to 20 ppb\n\nReceive L-arginine first, then Placebo\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}, {"id": "FG001", "title": "High Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo", "description": "Subjects with a baseline exhaled NO level greater than or equal to 25 ppb\n\nReceive L-arginine first, then Placebo\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}, {"id": "FG002", "title": "Low Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine", "description": "Subjects with a baseline exhaled NO level less than or equal to 20 ppb\n\nReceive Placebo first, then L-arginine\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}, {"id": "FG003", "title": "High Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine", "description": "Subjects with a baseline exhaled NO level greater than or equal to 25 ppb\n\nReceive L-arginine first, then Placebo\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}], "periods": [{"title": "First Intervention (12 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "13"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "13"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Washout (6 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "13"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}]}]}, {"title": "Second Intervention (12 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Low Exhaled Nitric Oxide (NO)", "description": "Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.\n\nBaseline characteristics at the enrollment"}, {"id": "BG001", "title": "High Exhaled Nitric Oxide (NO)", "description": "Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.\n\nBaseline characteristics at the enrollment"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "50"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.5", "spread": "11.9"}, {"groupId": "BG001", "value": "52.4", "spread": "14.3"}, {"groupId": "BG002", "value": "54.3", "spread": "13.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "38"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "39"}]}]}, {"title": "Non-White", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}]}]}, {"title": "Spirometry", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Litters", "classes": [{"title": "FEV1", "categories": [{"measurements": [{"groupId": "BG000", "value": "1.8", "spread": "0.7"}, {"groupId": "BG001", "value": "2.2", "spread": "0.9"}, {"groupId": "BG002", "value": "2", "spread": "0.8"}]}]}, {"title": "FVC", "categories": [{"measurements": [{"groupId": "BG000", "value": "2.6", "spread": "0.9"}, {"groupId": "BG001", "value": "2.8", "spread": "1.1"}, {"groupId": "BG002", "value": "2.7", "spread": "1.0"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "94.8", "spread": "20.5"}, {"groupId": "BG001", "value": "85.6", "spread": "27.3"}, {"groupId": "BG002", "value": "90.0", "spread": "24.5"}]}]}]}, {"title": "Asthma Control Test Score", "description": "The total Asthma Control Test score is reported. It is on a scale of 5 to 25. The higher the score, the better the asthma control. A score of 20 or more suggests good asthma control. A score of less than 20 suggests inadequate asthma control.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16.0", "spread": "4.6"}, {"groupId": "BG001", "value": "16.1", "spread": "5.5"}, {"groupId": "BG002", "value": "16.1", "spread": "5.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Acute Exacerbation at 3 Months", "description": "The primary endpoint of the study is the number of acute moderate exacerbations at 3 months. A moderate asthma exacerbation is defined as any of the following: 1) A drop in morning peak flow rate (PEFR) \\>30% from baseline on 2 consecutive days (1 event), 2) Need for initiation of oral steroids or am increased dose of inhaled corticosteroids on any two consecutive days (1 event), 3) Doubling of short-acting \u03b2-agonist use (e.g. number of puffs of albuterol) per day for 2 consecutive days (1 event).", "populationDescription": "Several patients dropped after the first intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Events", "timeFrame": "3 month", "groups": [{"id": "OG000", "title": "Low Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo", "description": "Subjects with a baseline exhaled NO level less than or equal to 20 ppb\n\nReceive L-arginine first, then Placebo\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}, {"id": "OG001", "title": "High Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo", "description": "Subjects with a baseline exhaled NO level greater than or equal to 25 ppb\n\nReceive L-arginine first, then Placebo\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}, {"id": "OG002", "title": "Low Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine", "description": "Subjects with a baseline exhaled NO level less than or equal to 20 ppb\n\nReceive Placebo first, then L-arginine\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}, {"id": "OG003", "title": "High Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine", "description": "Subjects with a baseline exhaled NO level greater than or equal to 25 ppb\n\nReceive L-arginine first, then Placebo\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"title": "First Intervention", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "2.0"}, {"groupId": "OG001", "value": "2.2", "spread": "2.2"}, {"groupId": "OG002", "value": "1.6", "spread": "1.8"}, {"groupId": "OG003", "value": "2.2", "spread": "3.0"}]}]}, {"title": "Second Intervention", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "13"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "1.4"}, {"groupId": "OG001", "value": "2.7", "spread": "4.2"}, {"groupId": "OG002", "value": "2.2", "spread": "2.2"}, {"groupId": "OG003", "value": "2.2", "spread": "2.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003"], "nonInferiorityType": "OTHER", "pValue": "0.78", "pValueComment": "The p-value is for the interaction term", "statisticalMethod": "testing for interaction term"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC)", "description": "The secondary endpoint is the change in FEV1/FVC ratio at 3 months. This calcuation is a ratio between the volume of breath exhaled in the first second divided by the total amount of breath exhaled in a vital capacity maneuver. A normal ratio is usually \\> 70%.", "populationDescription": "Several patients dropped after the first intervention", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "3 month", "groups": [{"id": "OG000", "title": "Low Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo", "description": "Subjects with a baseline exhaled NO level less than or equal to 20 ppb\n\nReceive L-arginine first, then Placebo\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}, {"id": "OG001", "title": "High Exhaled Nitric Oxide (NO), L-Arginine First, Then Placebo", "description": "Subjects with a baseline exhaled NO level greater than or equal to 25 ppb\n\nReceive L-arginine first, then Placebo\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}, {"id": "OG002", "title": "Low Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine", "description": "Subjects with a baseline exhaled NO level less than or equal to 20 ppb\n\nReceive Placebo first, then L-arginine\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}, {"id": "OG003", "title": "High Exhaled Nitric Oxide (NO), Placebo First, Then L-Arginine", "description": "Subjects with a baseline exhaled NO level greater than or equal to 25 ppb\n\nReceive L-arginine first, then Placebo\n\nL-Arginine: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.\n\nPlacebo: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"title": "First Intervention", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.05"}, {"groupId": "OG001", "value": "0.01", "spread": "0.06"}, {"groupId": "OG002", "value": "0.03", "spread": "0.13"}, {"groupId": "OG003", "value": "-0.03", "spread": "0.04"}]}]}, {"title": "Second Intervention", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "13"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.04"}, {"groupId": "OG001", "value": "0.13", "spread": "0.06"}, {"groupId": "OG002", "value": "0.003", "spread": "0.06"}, {"groupId": "OG003", "value": "-0.04", "spread": "0.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003"], "groupDescription": "The treatment effect was tested as an interaction term between treatment and FeNO. The null hypothesis is the effect of treatment is stratified by the FeNO status. We used a regression model instead of t-test or Wilcoxon signed-rank test in order to control period and carry-over effect which is common in a cross-over study design", "nonInferiorityType": "OTHER", "pValue": "0.09", "pValueComment": "The p-value is for the interaction term", "statisticalMethod": "testing for interaction term"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events were collected for the duration of the trial,8 months", "eventGroups": [{"id": "EG000", "title": "Low Exhaled Nitric Oxide (NO) Phase 1, Treatment Arm", "description": "ow Exhaled Nitric Oxide (NO) Phase 1, L-Arginine arm", "deathsNumAffected": 0, "deathsNumAtRisk": 11, "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 0, "otherNumAtRisk": 11}, {"id": "EG001", "title": "Low Exhaled Nitric Oxide (NO) Phase 1, Placebo Arm", "description": "Low Exhaled Nitric Oxide (NO) Phase 1, placebo arm", "deathsNumAffected": 0, "deathsNumAtRisk": 13, "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 1, "otherNumAtRisk": 13}, {"id": "EG002", "title": "Low Exhaled Nitric Oxide (NO) Washout Phase", "description": "Low Exhaled Nitric Oxide (NO) Washout Phase", "deathsNumAffected": 0, "deathsNumAtRisk": 19, "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 0, "otherNumAtRisk": 19}, {"id": "EG003", "title": "Low Exhaled Nitric Oxide (NO) Phase 2, Treatment Arm", "description": "Low Exhaled Nitric Oxide (NO) Phase 2, L-Arginine arm", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 1, "otherNumAtRisk": 10}, {"id": "EG004", "title": "Low Exhaled Nitric Oxide (NO) Phase 2, Placebo Arm", "description": "Low Exhaled Nitric Oxide (NO) Phase 2, placebo arm", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 0, "otherNumAtRisk": 9}, {"id": "EG005", "title": "High Exhaled Nitric Oxide (NO) Phase 1, Treatment Arm", "description": "High Exhaled Nitric Oxide (NO) Phase 1, L-Arginine arm", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 2, "seriousNumAtRisk": 12, "otherNumAffected": 1, "otherNumAtRisk": 12}, {"id": "EG006", "title": "High Exhaled Nitric Oxide (NO) Phase 1, Placebo Arm", "description": "High Exhaled Nitric Oxide (NO) Phase 1, placebo arm", "deathsNumAffected": 0, "deathsNumAtRisk": 14, "seriousNumAffected": 1, "seriousNumAtRisk": 14, "otherNumAffected": 0, "otherNumAtRisk": 14}, {"id": "EG007", "title": "High Exhaled Nitric Oxide (NO) Washout Phase", "description": "High Exhaled Nitric Oxide (NO) Washout Phase", "deathsNumAffected": 0, "deathsNumAtRisk": 22, "seriousNumAffected": 1, "seriousNumAtRisk": 22, "otherNumAffected": 0, "otherNumAtRisk": 22}, {"id": "EG008", "title": "High Exhaled Nitric Oxide (NO) Phase 2, Treatment Arm", "description": "High Exhaled Nitric Oxide (NO) Phase 2, L-Arginine arm", "deathsNumAffected": 0, "deathsNumAtRisk": 16, "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 0, "otherNumAtRisk": 16}, {"id": "EG009", "title": "High Exhaled Nitric Oxide (NO) Phase 2, Placebo Arm", "description": "igh Exhaled Nitric Oxide (NO) Phase 2, Placebo arm", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 0, "otherNumAtRisk": 6}], "seriousEvents": [{"term": "Hospitalization", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Subject was admitted to the hospital for exacerbation or flare of asthma either on placebo or L-arginine.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}]}], "otherEvents": [{"term": "Gastroesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}]}, {"term": "Hives", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG009", "numEvents": 0, "numAffected": 0, "numAtRisk": 6}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Nicholas Kenyon", "organization": "UC Davis", "email": "njkenyon@ucdavis.edu", "phone": "916-734-3564"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2019-12-15", "uploadDate": "2019-12-16T16:39", "filename": "Prot_SAP_000.pdf", "size": 198914}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000007249", "term": "Inflammation"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10293", "name": "Inflammation", "asFound": "Inflammation", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M12507", "name": "Nitric Oxide", "relevance": "LOW"}, {"id": "T1", "name": "Arginine", "asFound": "Capacity", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AA", "name": "Amino Acids"}]}}, "hasResults": true}